Not medical advice. The Journal of Biohacking reports published research and teaching models. Nothing on this page is medical advice, a diagnosis, or a recommendation to use any compound, product, or therapy. Where a dose appears, it is a figure reported in a cited study or by its sponsor, not an instruction. Editorial position on dosing.

Autoimmune cell therapy · Evidence grade D · 6 November 2026

The Reset Without the Chemotherapy: FT839

A research question, not a result. FT839 is designed to attempt an immune reset without the chemotherapy that other cell therapies use first. No person has received it.

Grade for the product: D. Sponsor statements and preclinical conference material. Zero human exposure.

The limits, first

The academic CAR-T studies that reported drug-free remission in lupus and rheumatoid arthritis begin with days of lymphodepleting chemotherapy, usually fludarabine and cyclophosphamide, before the cells are infused. In October 2026 Artiva Biotherapeutics discontinued its AlloNK programme after a patient died of leukoencephalopathy that investigators assessed as likely caused by the fludarabine conditioning, in a trial designed for outpatient rheumatology clinics. The cells were not blamed. The preparation was. That death is the reason the chemotherapy question is now the design question in this field.

FT839, from Fate Therapeutics, is the first product described by its sponsor as built from a blank page to ask whether deep immune depletion can be attempted without that chemotherapy. The grade stays D until a person has been treated and the result is reported.

What the sponsor says it built

FT839 is a CAR-T product manufactured from a single engineered induced-pluripotent stem-cell line, which is what “off the shelf” means here: no collection of the patient’s own cells, and no weeks of a bespoke batch for that one person. The sponsor describes two chimeric antigen receptors. One targets CD19, the B-cell marker used by the leading reset programmes. The other targets CD38, a marker on plasma cells, including long-lived plasma cells that can keep making autoantibodies after CD19-only depletion, and on activated T cells and other effector cells. Thirteen genetic edits are described, including Fate’s Sword and Shield technology, which the company says is meant to let the cells persist without the recipient first being lymphodepleted.

Read as design intent, that is a wider depletion than B cells alone, supplied like a drug from a freezer, with no chemotherapy in front of it. Design intent is not evidence. Whether it works is exactly what has not been tested in a person.

Where it actually stands

The FDA cleared an investigational new drug application in July 2026. The trial, called COMPLETE (sponsor designation FT839-101), is a single-arm Phase 1/2 basket covering rheumatoid arthritis, lupus, systemic sclerosis, ANCA-associated vasculitis and myositis. The sponsor says FT839 is given with background standard therapy and without conditioning chemotherapy. The sponsor-reported starting dose level is 900 million cells. That figure is the trial design as Fate described it. It is not a dose for anyone outside that trial, and the trial had not treated anyone when this page was written.

On 5 November 2026 Fate said multiple sites were activated and that the first patients, including people with rheumatoid arthritis, should be dosed by the end of the year. At ACR Convergence on 8 November, Fate’s poster on FT839 in rheumatoid arthritis is preclinical data and trial design, because that is all that exists.

There was not yet a public trial-registry record for COMPLETE as of 6 November 2026. Without that record there is no published site list and no eligibility criteria a patient or a rheumatologist can check independently. Until the record appears, access to the trial is a sponsor statement.

The sibling product, labelled as analogy

The only human evidence near FT839 belongs to a different product. FT819, Fate’s CD19-only off-the-shelf CAR-T, has been given to autoimmune patients in a Phase 1 trial (NCT06308978), using either a fludarabine-free conditioning regimen or, in one arm, no conditioning, with some patients treated as outpatients. By mid-2026 the sponsor had reported roughly 30 autoimmune patients treated. At a kidney conference in 2026, not yet peer-reviewed, the sponsor described a favourable safety profile so far and early renal responses in lupus nephritis. FT819 has moved to a Phase 2 trial in lupus nephritis (RECLAIM-LN).

That record suggests the platform can be delivered, and that a low-or-no-conditioning strategy has been tolerated in the patients treated so far. It does not show that FT839 is safe. It says nothing about whether FT839 works. A more heavily edited product with an extra target is a new risk profile, and this page grades it as one.

Why it is on a watch list

The reset hypothesis has the strongest published human reports of drug-free remission in this field, and its weaknesses are now specific: conditioning toxicity, manufacturing burden, and plasma cells that escape a single target. FT839 is a deliberate engineering response to those three, in the sponsor’s account. The public tests are dated. A registry record for COMPLETE. A first patient dosed. First human safety data. If those arrive, the grade can move, because the rest of the product is already built on paper. If the no-conditioning design fails in people, that failure is also information. Either way, the chemotherapy question now has a named product aimed at it, and no result.

Related pages: The Great Reset, Is there a cure for rheumatoid arthritis?, and the off-the-shelf CAR-NK question.

Sources

1. Fate Therapeutics public disclosures on the FT839 IND (July 2026), the COMPLETE trial design, the 5 November 2026 site update, and the ACR Convergence 2026 poster of preclinical data and trial design. Sponsor-reported. No human outcome is included because none exists.
2. Artiva Biotherapeutics, discontinuation of the AlloNK programme after a death assessed as likely related to fludarabine conditioning, October 2026, in company disclosures.
3. FT819 Phase 1, ClinicalTrials.gov NCT06308978, and sponsor presentations at ASN Kidney Week 2026, described above as conference-grade and not peer-reviewed. The renal-response figures are the sponsor’s, in small numbers.
4. The comparator reset reports named on The Great Reset: Mackensen et al., Nature Medicine 2022; Müller et al., New England Journal of Medicine 2024; the CASTLE basket trial, Nature Medicine 2026.

Research reporting only. Nothing on this page is medical advice or a recommendation for or against any treatment or trial.